Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer

Drug Safety

Volumn 24, Issue 5, 2001, Pages 353-367

  Jansman, F G A ^a   Sleijfer, D T ^b   De Graaf, J C ^a   Coenen, J L L M ^a   Brouwers, J R B J ^c,d  

^a Department of Clinical Pharmacy ^*  (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d General Hospital de Tjongerschans   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IRINOTECAN; OXALIPLATIN; RALTITREXED;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CARDIOTOXICITY; COLORECTAL CARCINOMA; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EYE TOXICITY; HAND FOOT AND MOUTH DISEASE; HUMAN; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SKIN DISEASE; SMALL INTESTINE DISEASE; VOMITING;

EID: 0035017339     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124050-00002     Document Type: Review

References (113)

1. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
2. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report
3. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
4. Palliative chemotherapy for advanced colorectal cancer: Systematic review and meta-analysis
5. New directions in the treatment of colorectal cancer: A look to the future
6. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
7. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer
8. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid
9. Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care
10. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer
11. Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
12. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study
13. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer
14. 5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: A pilot study
15. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previous untreated patients with advanced colorectal carcinoma
16. Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma
17. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial
18. Weekly high-dose leucovorin combined with fluorouracil in advanced colorectal cancer: Results of a randomized multicenter trial
19. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer
20. A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal carcinoma
21. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma
22. Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO)
23. A simplified regimen of weekly high dose 5-fluorouracil and leucovorin as a 24-hour infusion in patients with advanced colorectal carcinoma
24. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer
25. Weekly therapy with folinic acid and high-dose 5-fluorouracil 24-hour infusion in previously untreated patients with metastatic colorectal carcinoma
26. Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion
27. Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: A phase II study in patients with disseminated colorectal cancer
28. ZD1694: A novel thymidylate sunthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer
29. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
30. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer
31. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
32. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
33. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
34. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy
35. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
36. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-Fluorouracil (5-FU)
37. Two different schedules of irinotecan (CPT-11) administration in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil (5-FU)-leucovorin(FA) combination chemotherapy. Preliminary results of a randomized study
38. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients
39. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
40. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study
41. A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer
42. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer
43. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multi-centre randomised trial
44. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
45. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
46. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen
47. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen
48. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)
49. Oxaliplatin added to 5-fluorouracil-based therapy (5-FU±FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): Results from the European compassionate-use program
50. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: A Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study
51. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
52. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer
53. Hepatic arterial chemotherapy in metastatic colorectal patients
54. Waiting for the definitive trial of hepatic arterial chemotherapy for colorectal cancer
55. Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer
56. 5-FU therapeutic drug monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer
57. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: Results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients
58. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: Results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas
59. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: Relationship with mucosal toxicity in patients with cancer
60. Complete reversibility of mucositis and diarrhea induced by 5-fluorouracil in continuous infusion and 1-leucovorin by using a chrono-modulated schedule in advanced gastrointestinal cancer patients
61. Phase I trial of 5-day continuous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate
62. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors
63. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants
64. Chemoprotectants: A review of their clinical pharmacology and therapeutic efficacy
65. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
66. Update of recommendations for the use of hematopoietic colony-stimulating factors Evidence-based clinical practice guidelines
67. 1997 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
68. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
69. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy
70. Prevention and treatment of oral mucositis following cancer chemotherapy
71. Cancer therapy and oral mucositis. An appraisal of drug prophylaxis
72. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucosiris in patients receiving chemotherapy
73. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis
74. Soft-laser therapy for iatrogenic mucositis in cancer patients receiving high-dose fluorouracil: A preliminary report
75. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis
76. Inhibition of 5-fluorouracil-induced mucositis by oral cryotherapy
77. Colonic histologic changes induced by 5-fluorouracil
78. Recommended guidelines for the treatment of chemotherapy-induced diarrhea
79. CPT-11-induced cholinergic effects in cancer patients
80. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: A prospective assessment
81. Phase I and pharmacological studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients
82. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea
83. Glutamine for irinotecan diarrhea
84. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment
85. Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the Perugia Consensus Conference
86. Proposal for classifying the acute emetogenicity of cancer chemotherapy
87. Defining the emetogenicity of cancer chemotherapy regimens: Relevance to clinical practice
88. National Comprehensive Cancer Network Antiemesis Practice Guidelines, Vol. 2. NCCN proceedings
89. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors
90. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
91. Oxaliplatin. Pharmacokinetics and chronopharmacological aspects
92. Oxaliplatin: A review of preclinical and clinical studies
93. Oxaliplatin (L-OHP): Global safety in 682 patients (pts)
94. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome
95. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion
96. Hand-foot syndrome
97. Weekly fluorouracil and high-dose leucovorin: Efficacy and treatment of cutaneous toxicity
98. Ocular toxicity and cancer chemotherapy. A review
99. Inhibition of 5-fluorouracil-induced ocular irritation by ocular ice packs
100. Symptomatic cardiotoxicity associated with 5-fluorouracil
101. Cardiotoxicity of high dose continuous infusion fluorouracil: A prospective clinical study
102. Cardiotoxicity of the antiproliferative compound fluorouracil
103. Cardiotoxicity of chemotherapeutic agents
104. 5-Fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma
105. Haematological and nonhaematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number
106. Clinical pharmacokinetics of irinotecan
107. Raltitrexed: A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer
108. Prevention of chemotherapy-induced alopecia using an effective scalp cooling system
109. Where do we stand with 5-fluorouracil?